CN104540831B - 用于治疗癌症、自身免疫性炎症和cns紊乱的二氟二氧戊环‑氨基‑苯并咪唑激酶抑制剂 - Google Patents

用于治疗癌症、自身免疫性炎症和cns紊乱的二氟二氧戊环‑氨基‑苯并咪唑激酶抑制剂 Download PDF

Info

Publication number
CN104540831B
CN104540831B CN201380034461.4A CN201380034461A CN104540831B CN 104540831 B CN104540831 B CN 104540831B CN 201380034461 A CN201380034461 A CN 201380034461A CN 104540831 B CN104540831 B CN 104540831B
Authority
CN
China
Prior art keywords
alkyl
group
independently selected
conh
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380034461.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104540831A (zh
Inventor
约翰恩·莱班
米尔科·扎亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4sc Corp
Original Assignee
4SC Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4SC Discovery GmbH filed Critical 4SC Discovery GmbH
Publication of CN104540831A publication Critical patent/CN104540831A/zh
Application granted granted Critical
Publication of CN104540831B publication Critical patent/CN104540831B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201380034461.4A 2012-06-27 2013-06-27 用于治疗癌症、自身免疫性炎症和cns紊乱的二氟二氧戊环‑氨基‑苯并咪唑激酶抑制剂 Expired - Fee Related CN104540831B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664936P 2012-06-27 2012-06-27
US61/664,936 2012-06-27
EP12174669.7 2012-07-02
EP12174669 2012-07-02
PCT/EP2013/063537 WO2014001464A1 (en) 2012-06-27 2013-06-27 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Publications (2)

Publication Number Publication Date
CN104540831A CN104540831A (zh) 2015-04-22
CN104540831B true CN104540831B (zh) 2017-11-07

Family

ID=49782305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380034461.4A Expired - Fee Related CN104540831B (zh) 2012-06-27 2013-06-27 用于治疗癌症、自身免疫性炎症和cns紊乱的二氟二氧戊环‑氨基‑苯并咪唑激酶抑制剂

Country Status (19)

Country Link
US (2) US9580438B2 (https=)
EP (1) EP2867237A1 (https=)
JP (2) JP6272846B2 (https=)
KR (1) KR102155559B1 (https=)
CN (1) CN104540831B (https=)
AU (2) AU2013283318B2 (https=)
BR (1) BR112014032581A8 (https=)
CA (1) CA2877589C (https=)
EA (1) EA029718B1 (https=)
HK (1) HK1204474A1 (https=)
IL (1) IL236463A0 (https=)
IN (1) IN2014MN02562A (https=)
MX (1) MX350418B (https=)
MY (1) MY167785A (https=)
NZ (1) NZ702618A (https=)
SG (1) SG11201408617PA (https=)
UA (1) UA116541C2 (https=)
WO (1) WO2014001464A1 (https=)
ZA (1) ZA201409194B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013283318B2 (en) * 2012-06-27 2017-11-23 4Sc Ag Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
KR102416358B1 (ko) 2014-03-20 2022-07-07 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
KR102409739B1 (ko) 2014-03-20 2022-06-17 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
WO2017013210A1 (en) * 2015-07-21 2017-01-26 4Sc Ag Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds
WO2017053537A1 (en) 2015-09-23 2017-03-30 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
JP7837141B2 (ja) 2017-10-27 2026-03-30 シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法
BR112021003665A2 (pt) 2018-09-13 2021-05-18 Bayer Aktiengesellschaft derivados de heterocicleno como agentes de controle de pragas
CN109020990A (zh) * 2018-09-20 2018-12-18 广西壮族自治区药用植物园 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途
KR102119150B1 (ko) * 2018-10-23 2020-06-04 한국원자력의학원 N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
DK3643713T3 (da) * 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT
CN116942819A (zh) * 2023-04-24 2023-10-27 珠海市人民医院 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130673A1 (en) * 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
CN101528743A (zh) * 2006-07-14 2009-09-09 安姆根有限公司 稠合杂环衍生物及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167569A (en) 1976-12-09 1979-09-11 Imperial Chemical Industries Limited Pyrimido[1,2-a ]benzimidazole derivatives
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JO2724B1 (en) 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
ES2432361T3 (es) 2005-12-02 2013-12-03 Bayer Healthcare, Llc Derivados de pirrolotriazina útiles para el tratamiento de cáncer por inhibición de cinasa Aurora
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
EP2491030B1 (en) * 2009-10-22 2015-07-15 Fibrotech Therapeutics PTY LTD Fused ring analogues of anti-fibrotic agents
AU2013283318B2 (en) * 2012-06-27 2017-11-23 4Sc Ag Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130673A1 (en) * 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
CN101528743A (zh) * 2006-07-14 2009-09-09 安姆根有限公司 稠合杂环衍生物及使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
(H+,K+)-ATPase Inhibiting 2-[(2-Pyridylmethyl)sulfinyl]benzimidazoles. 4.A Novel Series of Dimethoxypyridyl-Substituted Inhibitors with Enhanced Selectivity. The Selection of Pantoprazole as a Clinical Candidate;Bernhard Kohl，等;《Journal of Medicinal Chemistry》;19920320;第35卷(第6期);第1049-1057页 *
2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε;Joachim Bischof，等;《Amino Acids》;20120214;第43卷(第4期);第1577-1591页 *

Also Published As

Publication number Publication date
AU2013283318B2 (en) 2017-11-23
JP6272846B2 (ja) 2018-01-31
UA116541C2 (uk) 2018-04-10
BR112014032581A8 (pt) 2018-08-14
ZA201409194B (en) 2017-08-30
IN2014MN02562A (https=) 2015-07-24
IL236463A0 (en) 2015-02-26
US9580438B2 (en) 2017-02-28
AU2018201275A1 (en) 2018-03-15
BR112014032581A2 (pt) 2017-06-27
NZ702618A (en) 2016-12-23
CN104540831A (zh) 2015-04-22
AU2013283318A1 (en) 2015-01-22
CA2877589A1 (en) 2014-01-03
MX350418B (es) 2017-09-06
US20150158878A1 (en) 2015-06-11
MX2014015938A (es) 2015-07-21
KR20150037877A (ko) 2015-04-08
CA2877589C (en) 2019-11-26
MY167785A (en) 2018-09-25
KR102155559B1 (ko) 2020-09-15
US20170240556A1 (en) 2017-08-24
EA201500050A1 (ru) 2015-09-30
SG11201408617PA (en) 2015-01-29
EP2867237A1 (en) 2015-05-06
JP2018076360A (ja) 2018-05-17
EA029718B1 (ru) 2018-05-31
WO2014001464A1 (en) 2014-01-03
HK1204474A1 (en) 2015-11-20
JP2015525742A (ja) 2015-09-07

Similar Documents

Publication Publication Date Title
CN104540831B (zh) 用于治疗癌症、自身免疫性炎症和cns紊乱的二氟二氧戊环‑氨基‑苯并咪唑激酶抑制剂
US11773110B2 (en) Heterocycle amines and uses thereof
KR100738862B1 (ko) 피리미딘 유도체
CA2996318C (en) Heteroaryl compounds as irak inhibitors and uses thereof
RU2559895C2 (ru) Азотосодержащие производные гетероарилов
TWI705963B (zh) 作為ｄｙｒｋ激酶抑制劑之2,3-二氫苯并呋喃-5-基化合物
AU2005228899A1 (en) Substituted thiophene derivatives as anti-cancer agents
KR20150074007A (ko) 3,4-이치환된 1h-피라졸 및 4,5-이치환된 티아졸 syk 억제제
US7915267B2 (en) Heterocyclic amide compound and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180211

Address after: Matt Ince Reed, German egger Champlain

Patentee after: 4SC Corp.

Address before: Matt Ince Reed, German egger Champlain

Patentee before: 4SC Discovery GmbH

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171107

CF01 Termination of patent right due to non-payment of annual fee